DDInter381 DDInter253
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood. It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life . XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. Most children with XLH suffer from bowed or bent legs, short stature, bone pain and severe dental pain. Some adults with this condition suffer from persistent, unrelenting discomfort and complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss .
Cinacalcet {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Cinacalcet {u} (Compound) palliates {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is palliated by {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Cinacalcet {u} (Compound) causes {v} (Side Effect) Muscle spasms
Muscle spasms {u} (Side Effect) is caused by {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Cinacalcet (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Cinacalcet (Compound) palliates chronic kidney failure (Disease) and chronic kidney failure (Disease) is palliated by Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Cinacalcet (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab